Patents by Inventor Derrick Y. Tarn

Derrick Y. Tarn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CATIONIC POLYMER COATED MESOPOROUS SILICA NANOPARTICLES AND USES THEREOF
    Publication number: 20190382265
    Abstract: A submicron structure having a silica body defining a plurality of pores is described. The submicron body may be spherical or non-spherical, and may include a cationic polymer or co-polymer on the surface of said silica body. The submicron structure may further include an oligonucleotide and be used to deliver the oligonucleotide to a cell. The submicron structure may further include a therapeutic agent and be used to deliver the therapeutic agent to a cell. An oligonucleotide and therapeutic agent may be used together. For example, when the oligonucleotide is an siRNA, the composition may be used to decrease cellular resistance to the therapeutic agent by decreasing translation of a resistance gene.
    Type: Application
    Filed: May 30, 2019
    Publication date: December 19, 2019
    Inventors: Jeffrey I. Zink, Andre E. Nel, Tian Xia, Zhaoxia Ji, Huan Meng, Zongxi Li, Monty Liong, Min Xue, Derrick Y. Tarn, Sanaz Gardner
  • Cationic polymer coated mesoporous silica nanoparticles and uses thereof
    Patent number: 10343903
    Abstract: A submicron structure having a silica body defining a plurality of pores is described. The submicron body may be spherical or non-spherical, and may include a cationic polymer or co-polymer on the surface of said silica body. The submicron structure may further include an oligonucleotide and be used to deliver the oligonucleotide to a cell. The submicron structure may further include a therapeutic agent and be used to deliver the therapeutic agent to a cell. An oligonucleotide and therapeutic agent may be used together. For example, when the oligonucleotide is an siRNA, the composition may be used to decrease cellular resistance to the therapeutic agent by decreasing translation of a resistance gene.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: July 9, 2019
    Assignee: The Regents of the University of California
    Inventors: Jeffrey I. Zink, Andre E. Nel, Tian Xia, Zhaoxia Ji, Huan Meng, Zongxi Li, Monty Liong, Min Xue, Derrick Y. Tarn, Sanaz Gardner
  • CATIONIC POLYMER COATED MESOPOROUS SILICA NANOPARTICLES AND USES THEREOF
    Publication number: 20180155189
    Abstract: A submicron structure having a silica body defining a plurality of pores is described. The submicron body may be spherical or non-spherical, and may include a cationic polymer or co-polymer on the surface of said silica body. The submicron structure may further include an oligonucleotide and be used to deliver the oligonucleotide to a cell. The submicron structure may further include a therapeutic agent and be used to deliver the therapeutic agent to a cell. An oligonucleotide and therapeutic agent may be used together. For example, when the oligonucleotide is an siRNA, the composition may be used to decrease cellular resistance to the therapeutic agent by decreasing translation of a resistance gene.
    Type: Application
    Filed: September 7, 2017
    Publication date: June 7, 2018
    Inventors: Jeffrey I. Zink, Andre E. Nel, Tian Xia, Zhaoxia Ji, Huan Meng, Zongxi Li, Monty Liong, Min Xue, Derrick Y. Tarn, Sanaz Kabehie
  • CATIONIC POLYMER COATED MESOPOROUS SILICA NANOPARTICLES AND USES THEREOF
    Publication number: 20120207795
    Abstract: A submicron structure having a silica body defining a plurality of pores is described. The submicron body may be spherical or non-spherical, and may include a cationic polymer or co-polymer on the surface of said silica body. The submicron structure may further include an oligonucleotide and be used to deliver the oligonucleotide to a cell. The submicron structure may further include a therapeutic agent and be used to deliver the therapeutic agent to a cell. An oligonucleotide and therapeutic agent may be used together. For example, when the oligonucleotide is an siRNA, the composition may be used to decrease cellular resistance to the therapeutic agent by decreasing translation of a resistance gene.
    Type: Application
    Filed: March 23, 2012
    Publication date: August 16, 2012
    Applicant: The Regents of the University of California
    Inventors: Jeffrey I. Zink, Andre E. Nel, Tian Xia, Zhaoxia Ji, Huan Meng, Zongxi Li, Monty Liong, Min Xue, Derrick Y. Tarn